| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
D-Sedoheptulose 7-phosphate is a substrate for several enzymes in the pentose phosphate pathway, including transketolase and transaldolase. It serves as a precursor for the synthesis of nucleotide sugars and aromatic amino acids. In the non-oxidative phase of the PPP, D-sedoheptulose 7-phosphate reacts with D-glyceraldehyde 3-phosphate to form D-ribose 5-phosphate and D-xylulose 5-phosphate, catalyzed by transketolase. It also reacts with D-glyceraldehyde 3-phosphate to form β-D-fructofuranose 6-phosphate and D-erythrose 4-phosphate, catalyzed by transaldolase.
|
|---|---|
| ln Vitro |
ADP-sugar involved in microbial natural product biosynthesis, SepB, SepL, and SepC can convert sedoheptulose 7-phosphate to ADP-l-glycerol-β-d-mannoheptose [1]. SepL is involved in the biosynthesis of heptose in the core area of E, while SepB is an S-7-P isomerase. Coli LPS. The four-reaction relay d that transforms S-7-P into ADP-d-glycerol-β--mannoheptose is catalyzed by them[1]. Analogs of septacidin show promise as analgesics and anticancer drugs [1]. In fact, pig and poultry farming uses the anthelmintic Hygromycin B [1].
In vitro, D-sedoheptulose 7-phosphate is used as a substrate in enzyme assays to measure the activity of transketolase and transaldolase. The compound is also used in studies of the pentose phosphate pathway to investigate the regulation of glucose metabolism. In cell-free systems, the conversion of D-sedoheptulose 7-phosphate to other metabolites can be monitored spectrophotometrically by coupling the reactions to NADPH-dependent enzymes. The compound's role in the production of NADPH makes it a key molecule in studies of oxidative stress and redox balance. |
| ln Vivo |
In vivo, D-sedoheptulose 7-phosphate is an essential intermediate in glucose metabolism, and its levels are tightly regulated. Alterations in the pentose phosphate pathway, and consequently in the levels of D-sedoheptulose 7-phosphate, have been implicated in various diseases, including cancer and metabolic disorders. The compound is not administered as a therapeutic agent but is studied as a biomarker of metabolic flux. Its role in providing precursors for nucleotide and aromatic amino acid biosynthesis is critical for cell proliferation and survival.
|
| Enzyme Assay |
In vitro enzyme assays for D-sedoheptulose 7-phosphate involve measuring the activity of enzymes that utilize this compound as a substrate. For transketolase, the assay is performed by incubating the enzyme with D-sedoheptulose 7-phosphate and D-glyceraldehyde 3-phosphate in a buffer containing thiamine pyrophosphate and magnesium ions. The formation of D-ribose 5-phosphate and D-xylulose 5-phosphate is measured spectrophotometrically or by HPLC. For transaldolase, the assay is performed by incubating the enzyme with D-sedoheptulose 7-phosphate and D-glyceraldehyde 3-phosphate, and the formation of β-D-fructofuranose 6-phosphate and D-erythrose 4-phosphate is measured.
|
| Cell Assay |
In vitro cellular experiments for D-sedoheptulose 7-phosphate involve studying its role in the pentose phosphate pathway in cultured cells. Cells are treated with metabolic inhibitors or activators to modulate the flux through the PPP, and the levels of D-sedoheptulose 7-phosphate are measured by LC-MS. The compound's role in NADPH production and redox balance is assessed by measuring the ratio of NADPH to NADP+ and the levels of reduced glutathione. The effect of modulating the PPP on cell proliferation and survival is also studied.
|
| Animal Protocol |
In vivo animal studies for D-sedoheptulose 7-phosphate involve measuring its levels in tissues under different physiological and pathological conditions. The compound is extracted from tissues and analyzed by LC-MS or enzymatic assays. Its levels are often used as a marker of metabolic flux through the pentose phosphate pathway. Studies in animal models of cancer, diabetes, and neurodegenerative diseases have investigated alterations in the PPP and the levels of D-sedoheptulose 7-phosphate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not typically studied for D-sedoheptulose 7-phosphate, as it is an endogenous metabolite rather than a therapeutic agent. However, its levels in the body are dynamically regulated in response to metabolic demands. The compound is synthesized from glucose-6-phosphate via the oxidative phase of the pentose phosphate pathway and is metabolized in the non-oxidative phase. Its concentration in cells is typically in the micromolar range.
|
| Toxicity/Toxicokinetics |
Toxicology is not applicable to D-sedoheptulose 7-phosphate, as it is an endogenous metabolite rather than a therapeutic agent. The compound is naturally present in all cells and is not known to be toxic. However, abnormal accumulation or depletion of this metabolite can be a sign of metabolic dysfunction. The compound is considered safe for handling in the laboratory under standard safety precautions.
|
| References | |
| Additional Infomation |
Sedum heptulose-7-phosphate is a ketohexose phosphate composed of sedum heptulose with a phosphate group attached at the 7-position. It is an intermediate metabolite in the pentose phosphate pathway. It is found in humans, E. coli, and mice, and is a derivative of sedum heptulose and a ketohexose phosphate, functionally related to sedum heptulose. It is the conjugate acid of sedum heptulose-7-phosphate (2-). D-Sedum heptulose-7-phosphate is a metabolite found in or produced by E. coli (K12 strain, MG1655 strain). Sedum heptulose-7-phosphate has also been reported in Drosophila melanogaster, Aspen, and other organisms with relevant data. Sedum heptulose-7-phosphate is a metabolite found in or produced by Saccharomyces cerevisiae.
D-Sedoheptulose 7-phosphate is a key intermediate in the pentose phosphate pathway, linking the oxidative and non-oxidative phases. It plays a crucial role in the generation of NADPH for reductive syntheses and oxidative stress responses, and the formation of ribose residues for nucleotide and nucleic acid biosynthesis. This compound is essential for maintaining redox balance and providing precursors for biosynthetic processes. It is also a precursor for the heptoses of septacidin and hygromycin B. As an endogenous metabolite, D-sedoheptulose 7-phosphate is a valuable biomarker for studying metabolic flux and disease states. |
| Molecular Formula |
C7H13O10P-2
|
|---|---|
| Molecular Weight |
288.14592
|
| Exact Mass |
425.93
|
| CAS # |
2646-35-7
|
| PubChem CID |
165007
|
| Appearance |
White to yellow solid powder
|
| Density |
1.862g/cm3
|
| Boiling Point |
751.4ºC at 760mmHg
|
| Flash Point |
408.3ºC
|
| Vapour Pressure |
4.61E-26mmHg at 25°C
|
| Index of Refraction |
1.605
|
| LogP |
-5
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
18
|
| Complexity |
313
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C([C@H]([C@H]([C@H]([C@@H](C(=O)CO)O)O)O)O)OP(=O)(O)O
|
| InChi Key |
JDTUMPKOJBQPKX-GBNDHIKLSA-N
|
| InChi Code |
InChI=1S/C7H15O10P/c8-1-3(9)5(11)7(13)6(12)4(10)2-17-18(14,15)16/h4-8,10-13H,1-2H2,(H2,14,15,16)/t4-,5-,6-,7+/m1/s1
|
| Chemical Name |
[(2R,3R,4R,5S)-2,3,4,5,7-pentahydroxy-6-oxoheptyl] dihydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4704 mL | 17.3521 mL | 34.7041 mL | |
| 5 mM | 0.6941 mL | 3.4704 mL | 6.9408 mL | |
| 10 mM | 0.3470 mL | 1.7352 mL | 3.4704 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
